CX-1739 is under clinical development by RespireRx Pharmaceuticals and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect CX-1739’s likelihood of approval (LoA) and phase transition for Respiratory Depression (Hypoventilation) took place on 03 May 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their CX-1739 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

CX-1739 overview

CX-1739 is under development for the treatment of opiate-induced respiratory depression, spinal cord injury, Pompe disease, autism spectrum disorders including Fragile X Syndrome, perinatal respiratory distress and chronic and post-surgical central sleep apnea. It is administered orally. CX1739 is a low impact third generation ampakine. It acts by targeting ampakine receptors. It is developed using Ampakine technology. It was also under development for attention-deficit hyperactivity disorder and obstructive sleep apnea.

RespireRx Pharmaceuticals overview

RespireRx Pharmaceuticals (RespireRx), formerly Cortex Pharmaceuticals, Inc. involved in the discovery, development, and commercialization of innovative products for the treatment of various respiratory disorders (RD) and CNS problems. RespireRx focuses on attention deficit hyperactivity disorder, obstructive sleep apnea (OSA), spinal cord injury and other neurological disorders. The company’s lead product is Dronabinol, an oral capsule drug product which is being evaluated for the treatment of OSA. The company’s other pipeline products include CX1739, CX717, CX1942 and others. RespireRx is headquartered in Glen Rock, New Jersey, the US.

Quick View CX-1739 LOA Data

Report Segments
  • Innovator
Drug Name
  • CX-1739
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Genetic Disorders
  • Metabolic Disorders
  • Respiratory
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.